Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China · Delayed Price · Currency is CNY 25.88
+0.83 (3.31%)
Aug 31, 2026, 3:00 PM CST
SHA:600566 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 23,088 | 24,228 | 26,803 | 28,972 | 25,092 | 25,173 | |
Market Cap Growth | -3.40% | -9.61% | -7.49% | 15.47% | -0.32% | 40.09% |
Enterprise Value | 12,778 | 14,049 | 16,353 | 19,711 | 18,865 | 20,556 |
Last Close Price | 25.05 | 24.57 | 25.20 | 26.27 | 22.06 | 22.31 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.52 | 13.63 | 10.59 | 10.26 | 11.56 | 14.64 |
Forward PE | - | 10.76 | 8.82 | 11.02 | 11.16 | 13.64 |
PS Ratio | 3.98 | 3.90 | 3.34 | 3.00 | 2.79 | 3.30 |
PB Ratio | 1.67 | 1.66 | 1.82 | 2.17 | 2.21 | 2.76 |
P/TBV Ratio | 1.75 | 1.72 | 1.88 | 2.25 | 2.31 | 2.90 |
P/FCF Ratio | 28.70 | 21.98 | 13.39 | 9.16 | 10.56 | 15.29 |
P/OCF Ratio | 21.37 | 20.22 | 12.32 | 8.36 | 9.57 | 13.29 |
PEG Ratio | - | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.20 | 2.26 | 2.04 | 2.04 | 2.10 | 2.69 |
EV/EBITDA Ratio | 5.97 | 6.52 | 5.98 | 6.19 | 7.37 | 10.47 |
EV/EBIT Ratio | 6.97 | 7.58 | 6.74 | 6.84 | 8.37 | 12.31 |
EV/FCF Ratio | 15.88 | 12.74 | 8.17 | 6.23 | 7.94 | 12.49 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.10 | 0.05 | 0.06 | 0.08 | 0.04 | 0.07 |
Debt / EBITDA Ratio | 0.67 | 0.33 | 0.31 | 0.34 | 0.16 | 0.32 |
Debt / FCF Ratio | 1.78 | 0.65 | 0.42 | 0.35 | 0.17 | 0.38 |
Net Debt / Equity Ratio | -0.75 | -0.75 | -0.75 | -0.73 | -0.66 | -0.53 |
Net Debt / EBITDA Ratio | -4.84 | -5.10 | -4.02 | -3.08 | -2.91 | -2.48 |
Net Debt / FCF Ratio | -12.85 | -9.96 | -5.49 | -3.11 | -3.14 | -2.95 |
Asset Turnover | 0.34 | 0.34 | 0.44 | 0.58 | 0.66 | 0.67 |
Inventory Turnover | 3.03 | 2.98 | 3.15 | 4.05 | 4.01 | 3.90 |
Quick Ratio | 4.36 | 4.81 | 3.99 | 2.99 | 3.13 | 2.75 |
Current Ratio | 4.52 | 4.93 | 4.16 | 3.10 | 3.26 | 2.90 |
Return on Equity (ROE) | 13.42% | 12.11% | 18.06% | 22.87% | 21.20% | 20.33% |
Return on Assets (ROA) | 6.80% | 6.41% | 8.29% | 10.88% | 10.39% | 9.22% |
Return on Invested Capital (ROIC) | 42.90% | 41.33% | 56.80% | 66.53% | 47.85% | 34.95% |
Return on Capital Employed (ROCE) | 13.10% | 12.50% | 16.30% | 21.30% | 19.50% | 17.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.96% | 7.34% | 9.45% | 9.74% | 8.65% | 6.83% |
FCF Yield | 3.48% | 4.55% | 7.47% | 10.91% | 9.47% | 6.54% |
Dividend Yield | 7.25% | 7.08% | 8.29% | 4.95% | 3.99% | 3.05% |
Payout Ratio | 88.20% | 108.48% | 48.10% | 29.16% | 27.89% | 23.81% |
Buyback Yield / Dilution | 0.21% | -0.43% | -0.08% | -0.91% | -0.91% | -7.82% |
Total Shareholder Return | 7.46% | 6.65% | 8.21% | 4.04% | 3.08% | -4.78% |